Humira (adalimumab)
Research Synopsis
- Recent research on Humira (adalimumab) highlights its efficacy in treating various conditions, particularly moderate-to-severe psoriasis where over 1,150 patients showed significant improvement in skin condition during long-term treatment.
- Factors such as gender, weight, and previous treatments were identified to influence the effectiveness of adalimumab in psoriasis patients.
- Research indicates that a systematic review found cases of bullous pemphigoid linked to biologic therapies, stressing the importance of monitoring patients for skin reactions.
- Adalimumab has been used effectively as an induction therapy for Crohn's disease, with around 41% of patients achieving clinical remission within 12 weeks.
- The recent studies confirm the continued relevance of monitoring treatment responses and predicting outcomes based on biomarkers like oncostatin M in anti-TNF therapies.
- New biosimilars of adalimumab are being researched, showing similar efficacy and safety profiles compared to the original drug, paving the way for more affordable treatment options.
- The efficacy of adalimumab was assessed in patients with Vogt-Koyanagi-Harada syndrome, showing beneficial effects for newly diagnosed cases, although it did not prevent relapses.
- A notable study found that many children were increasingly treated for psoriasis over the years, with varying retention rates for different medications, highlighting adalimumab's role among other systemic therapies.
- The EULAR guidelines emphasize the importance of incorporating patient-specific factors in treatment planning for rheumatoid arthritis, where adalimumab is also widely used.
- Overall, the research continues to underscore the importance of personalized medicine, monitoring, and the growing landscape of biosimilars in adalimumab therapy.
Humira (adalimumab)
Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic.
London, UK
2 hours ago
1 Received
- The study looked at how well a medicine called adalimumab works for patients with psoriasis in the Czech Republic from 2005 to 2018.
- Over 1,150 patients were treated, and many showed a big improvement in their skin condition after 12 and 96 months on the medicine.
- The study found that things like being female, being overweight, and having taken other treatments before can make the medicine work less well for some people.
$100 - $150
Hourly Rate
Treatment utilization and drug survival of systemic medications among commercially insured children with psoriasis.
London, UK
2 hours ago
1 Received
- The study looked at how kids with psoriasis are treated with medications and light therapy in the United States.
- It found that more kids were getting these treatments from 2001 to 2016, with different medications lasting varying times before being stopped.
- Some medications like ustekinumab and etanercept worked better than others, meaning kids stayed on those treatments longer before stopping.
$100 - $150
Hourly Rate
Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review.
London, UK
2 hours ago
1 Received
- Some people with psoriasis might get a skin problem called bullous pemphigoid (BIBP) from medicines called biologics that they take for their psoriasis.
- Researchers looked at many studies to find out how often this happens and how serious it can be.
- They found 15 cases of BIBP linked to different biologic medicines, with ustekinumab causing the most instances, and it's really important for doctors to watch their patients’ skin closely when using these treatments.
$100 - $150
Hourly Rate
Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab.
London, UK
2 hours ago
1 Received
- Oncostatin M is a helpful blood marker that can show how well certain medicines work for people with inflammatory bowel diseases (IBD), especially when using anti-TNF drugs like infliximab.
- The study looked at two groups of IBD patients to see how well their treatment worked after 54 weeks, measuring oncostatin M and other markers in their blood and stool.
- Results showed that lower levels of oncostatin M before treatment were linked to better healing in patients taking anti-TNF drugs, but not in those on vedolizumab, indicating that oncostatin M is useful for predicting treatment success with anti-TNF medications.
$100 - $150
Hourly Rate
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
London, UK
2 hours ago
1 Received
- The EULAR group updated recommendations for treating rheumatoid arthritis (RA) by looking into new research about medications and their safety.
- They focused on different types of drugs like DMARDs and glucocorticoids, and set rules based on the best evidence from studies.
- The task force created 5 main principles and 11 recommendations to help doctors decide the best treatment plans, considering factors like effectiveness, safety, and cost.
$100 - $150
Hourly Rate
Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.
London, UK
2 hours ago
1 Received
- Psoriasis is a long-lasting skin condition, and adalimumab is a treatment that used to be very expensive, but now cheaper versions called biosimilars are available after the original product's patent ran out.
- This study aims to compare how well the biosimilars work and how safe they are compared to the original adalimumab by looking at real patient data from different countries.
- The researchers will share their findings in scientific journals and at dermatology conferences by the end of 2023, following ethical guidelines.
$100 - $150
Hourly Rate
The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study.
London, UK
2 hours ago
1 Received
- The study looked at how certain treatments can unexpectedly cause skin problems like paradoxical psoriasis in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA).
- Out of thousands of patients, about 136 had these unexpected skin problems, mostly after taking specific medications, and most patients were switched to new treatments to help.
- The results showed that switching medications usually worked well, and certain groups of patients, like smokers, were impacted differently by these skin reactions.
$100 - $150
Hourly Rate
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
London, UK
2 hours ago
1 Received
- The study looked at how antidrug antibodies affect the effectiveness of certain medications for treating rheumatoid arthritis (RA).
- It involved 254 patients from 27 centers across four European countries, who were starting new biologic treatments.
- Researchers measured the levels of these antibodies and patients' responses to the treatment at different times to better understand their connection.
$100 - $150
Hourly Rate
Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate.
London, UK
2 hours ago
1 Received
- Researchers studied a medicine called filgotinib to see if it helps people with moderately active rheumatoid arthritis (RA) who weren't getting better with other treatments.
- They tested filgotinib against a placebo and another medicine called adalimumab, finding that more patients on filgotinib felt better and had less disease activity after 12 and 24 weeks.
- The safety of filgotinib was similar to adalimumab, with infections being the most common side effect, and the benefits lasted for at least a year.
$100 - $150
Hourly Rate
Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research.
London, UK
2 hours ago
1 Received
- Chronic anterior uveitis (CAU) can cause serious eye problems, so doctors created treatment plans to help kids with it.
- The study looked at how these treatment plans worked for kids with a type of arthritis-related eye condition, tracking their medicine and eye health over time.
- Results showed that most kids had good control of their uveitis after six months, and both treatment plans were successfully used in real-life doctor visits.
$100 - $150
Hourly Rate
A complex case of PASH syndrome: pyoderma gangrenosum, acne, suppurative hidradenitis, and Crohn's disease in a 36-year-old smoker.
London, UK
2 hours ago
1 Received
- PASH syndrome is an autoimmune condition that causes skin problems like acne and painful sores, which get worse over time.
- A 36-year-old man had severe symptoms including skin ulcers and struggled to find effective treatments until he improved using Infliximab.
- Treating PASH syndrome is tricky because it can be linked to other health issues, and doctors need to try different therapies to see what works best for each patient.
$100 - $150
Hourly Rate
Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease.
London, UK
2 hours ago
1 Received
- The study looked at how well a medicine called adalimumab works for people with a disease called Vogt-Koyanagi-Harada syndrome, focusing on both new cases and those that come back.
- Researchers compared 22 patients who took adalimumab with 22 who did not take it, measuring changes in their eye health and symptoms.
- They found that adalimumab helped improve eye health in new cases but did not prevent relapses in patients whose symptoms came back.
$100 - $150
Hourly Rate
Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.
London, UK
2 hours ago
1 Received
- Vogt-Koyanagi-Harada (VKH) disease is an autoimmune disorder that affects the eyes and can cause vision problems and skin changes like vitiligo (white patches on the skin).
- It often happens in people with a certain genetic background, especially those from Asian or Hispanic backgrounds.
- A case of a 40-year-old woman with VKH showed eye pain, vision loss, and vitiligo, along with other symptoms like redness in her eyes and swelling around the optic nerve.
$100 - $150
Hourly Rate
Common practice patterns in the diagnosis and management of Vogt-Koyanagi-Harada syndrome: a survey study of uveitis specialists.
London, UK
2 hours ago
1 Received
- VKH syndrome is a serious eye condition that can cause inflammation and affects around 18% of patients referred to eye specialists in the U.S.
- An online survey was conducted with eye doctors to find out how they diagnose and treat VKH, asking about their methods and what medicines they prefer.
- Most doctors agree on certain diagnostic tools and prefer using a combination of high-dose steroids and certain therapies, but there isn’t a clear agreement on the best treatments for all cases.
$100 - $150
Hourly Rate
A Novel Frameshift Variant of the ELF4 Gene in a Patient with Autoinflammatory Disease: Clinical Features, Transcriptomic Profiling and Functional Studies.
London, UK
2 hours ago
1 Received
- A patient was diagnosed with a rare disease called DEX, caused by a new change in a gene called ELF4.
- Tests showed that this change affected the patient's immune system and caused inflammation in his body.
- The boy was treated with medication that helped a lot, and the study explained how the gene change relates to his illness and treatment.
$100 - $150
Hourly Rate
Clinical and histological changes in Hidradenitis suppurativa following 1064 nm nd:YAG intralesional laser treatment.
London, UK
2 hours ago
1 Received
- - Hidradenitis Suppurativa (HS) is often misdiagnosed for years, limiting treatment options and causing embarrassment for young patients when it affects sensitive areas like the inguinal region.
- - Delayed diagnosis can worsen symptoms, leading to severe stages of the disease that may require aggressive treatments like surgical procedures or strong medications such as anti-TNF-alpha drugs.
- - The study introduces a low-invasive treatment with positive outcomes for early-stage HS, emphasizing the need for improved awareness and early diagnosis among both healthcare providers and patients.
$100 - $150
Hourly Rate
Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease:
London, UK
2 hours ago
1 Received
- - The study evaluates the effectiveness and cost-effectiveness of therapeutic monitoring of TNF-α inhibitors in treating moderate to severe Crohn's disease, comparing different ELISA test kits against standard care.
- - A systematic review of electronic databases was conducted, focusing on patient outcomes, test accuracy, and cost estimates, leading to the inclusion of 68 primary studies and 4 cost-effectiveness studies.
- - A detailed economic model was created to analyze long-term outcomes from a healthcare perspective, highlighting the potential benefits and costs associated with using monitoring tests for TNF-α therapies.
$100 - $150
Hourly Rate
[Adalimumab as induction therapy for Crohn's disease - one center study].
London, UK
2 hours ago
1 Received
- Adalimumab is a fully human monoclonal antibody approved in Poland since 2010 for treating Crohn's disease, specifically for inducing clinical remission in patients with active disease.
- The study evaluated 68 patients treated with adalimumab, measuring effectiveness via the Crohn's Disease Activity Index (CDAI) after 12 weeks, with 41% achieving clinical remission and 49% showing significant improvement.
- While adalimumab is effective for moderate-to-severe Crohn's disease, serious infections can occur, and factors like being female, non-smoking, and having a high baseline CRP level may predict better outcomes.
$100 - $150
Hourly Rate
Clinical Evaluation of Humira Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics.
London, UK
2 hours ago
1 Received
- ONS-3010, developed by Oncobiologics as a biosimilar to Humira, underwent a phase I study to compare its pharmacokinetics, safety, and immunogenicity to both EU and US versions of Humira in healthy volunteers.
- The study involved 198 participants who received a single dose of either ONS-3010 or Humira, with results showing similar pharmacokinetic profiles and immune responses across treatment groups.
- Additionally, the research highlighted the effectiveness of ONS-3010 in significantly lowering TNFα levels and interleukin-8 release in response to specific immune challenges, indicating its potential for further clinical development.
$100 - $150
Hourly Rate
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
London, UK
2 hours ago
1 Received
- This Phase I study (VOLTAIRE®-PK) assessed the pharmacokinetic similarity, safety, and immune response of BI 695501, a biosimilar to Humira, compared to US- and EU-approved versions of Humira in healthy men.
- A total of 327 participants were randomly assigned to receive either BI 695501 or a Humira version, and the drugs' bioequivalence was confirmed with confidence intervals within the accepted range.
- Results showed that BI 695501 was bioequivalent to both forms of Humira, with similar safety profiles and immune responses across all groups.
$100 - $150
Hourly Rate